The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets
- 8 August 2020
- book chapter
- Published by Springer Nature
- Vol. 1258, 157-166
Abstract
Aldehyde dehydrogenases are a family of enzymes that oxidize aldehydes to carboxylic acids. These enzymes are important in cellular homeostasis during oxidative stress by the elimination of toxic aldehyde by-products from various cellular processes. In osteosarcoma, aldehyde dehydrogenase 1A1has been described as a cancer stem cell marker. Its activity has been found to correlate with metastatic potential and the metastatic phenotype. As such, a more complete understanding of aldehyde dehydrogenase in osteosarcoma will give us a deeper knowledge of its impact on osteosarcoma metastatic potential. Our hope is that this knowledge can be translated into novel antimetastatic therapeutic strategies and thus improve osteosarcoma prognoses.Keywords
This publication has 32 references indexed in Scilit:
- Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical ApplicationPharmacological Reviews, 2012
- Good prognosis of localized osteosarcoma in young patients treated with limb‐salvage surgery and chemotherapyPediatric Blood & Cancer, 2011
- Retinoids, Retinoic Acid Receptors, and CancerAnnual Review of Pathology: Mechanisms of Disease, 2011
- Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistanceOncology Reports, 2010
- Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast CancerClinical Cancer Research, 2010
- Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon TumorigenesisCancer Research, 2009
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potentialLeukemia, 2007
- Current strategies of chemotherapy in osteosarcomaInternational Orthopaedics, 2006
- Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma GroupsJournal of Clinical Oncology, 2005